
Astellas Licenses XNW27011 ADC from Evopoint Biosciences
Astellas Pharma Inc. and Evopoint Biosciences announced they have entered into an exclusive license agreement for XNW27011, a novel investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2. The agreement grants Astellas a worldwide ( …